Regeneron to Acquire Decibel Therapeutics to Advance Gene Therapy and Hearing Loss Programs
Shots:
- Regeneron to acquire Decibel at a price of $4.00 per share of Decibel common stock representing a 43% premium over its closing price of $2.79, non-tradeable CVR of ~$3.50/share upon achievement of development & regulatory milestones for Decibel’s DB-OTO representing a total equity value of ~$109M based on the amount payable at closing & ~$213M if CVR milestones are achieved. The transaction is expected to close in Q3’23
- Regeneron focuses to strengthen its genetic medicines portfolio by using Decibel’s assets & specialized team to advance the development of innovative genetic therapies and a rich pipeline of hearing loss treatments
- Decibel & Regeneron collaborated in 2017 & extension was announced in 2021 with a focus on 3 gene therapy programs targeting different forms of congenital, monogenic hearing loss. DB-OTO is currently being studied in the P-I/II trial (CHORD)
Ref: GlobeNewswire | Image: Regeneron
Related News:- Regeneron Presented Two-Year Results from (PHOTON) Trial of Aflibercept for Diabetic Macular Edema at ASRS 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
